Pharmaceutical News – Page 33 – Global Reach Health

April 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Single-Batch-of-Lantus-Generic-Recalled-480x360.jpg" class="scale-with-grid wp-post-image" alt="Single-Batch-of-Lantus-Generic-Recalled" decoding="async" />

Single-Batch-of-Lantus-Generic-Recalled

Single Batch of Lantus Generic Recalled

March 29, 2022 – Teva Pharmaceuticals has recalled lot 31329657B of IDArubicin Hydrochloride Injection USP 5mg/5mL vials. An internal inspection found one vial contained silica

April 14, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Imcivree-Approved-in-Treatment-of-Two-Rare-Genetic-Disorders-480x360.jpg" class="scale-with-grid wp-post-image" alt="Imcivree-Approved-in-Treatment-of-Two-Rare-Genetic-Disorders" decoding="async" />

Imcivree-Approved-in-Treatment-of-Two-Rare-Genetic-Disorders

Imcivree Approved in Treatment of Two Rare Genetic Disorders

April 14, 2022 – The U.S. FDA has approved Imcivree^® (setmelanotide) for treatment of obesity and control of hunger in patients who are at least six years old and have Bardet-Biedl

April 13, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Avastin-Biosimilar-Alymsys-Granted-Approval-480x360.jpg" class="scale-with-grid wp-post-image" alt="Avastin-Biosimilar-Alymsys-Granted-Approval" decoding="async" />

Avastin-Biosimilar-Alymsys-Granted-Approval

Avastin Biosimilar Alymsys Granted Approval

April 13, 2022 – Amneal has received FDA approval for Alymsys^® (bevacizumab-maly) intravenous injection, a biosimilar to Genentech’s Avastin^®

April 11, 2022

<img width="480" height="360" src="https://sp-ao.shortpixel.ai/client/to_auto,q_glossy,ret_img,w_480,h_360/https://www.globalreachhealth.com/wp-content/uploads/2022/04/Xigduo-XR-Receives-New-Indication-for-Kidney-Disease-480x360.jpg" class="scale-with-grid wp-post-image" alt="Xigduo-XR-Receives-New-Indication-for-Kidney-Disease" decoding="async" />

Xigduo-XR-Receives-New-Indication-for-Kidney-Disease

Xigduo XR Receives New Indication for Kidney Disease

April 11, 2022 – Xigduo^® XR (dapagliflozin/metformin) has received a new indication for one of its active pharmaceutical ingredients (APIs), dapagliflozin, to reduce the risk of

April 8, 2022

ArmonAir Now Indicated for Younger Patient Population

April 8, 2022 – ArmonAir^® Digihaler^® (fluticasone propionate) has received an expanded indication to provide maintenance treatment (as prophylactic therapy) for asthma in patients

April 6, 2022

Vijoice Approved to Treat Group of Rare Genetic Disorders

April 6, 2022 – Novartis has obtained FDA approval for Vijoice^® (alpelisib) to treat severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in patients at least two years of age

April 6, 2022

New Acute Treatment Option for Schizophrenia and Bipolar Disorder

April 6, 2022 – Igalmi^TM (dexmedetomidine) sublingual film, made by BioXcel Therapeutics, has received FDA approval to treat agitation associated with schizophrenia

April 1, 2022

Yescarta Granted Approval for Earlier Use in B-Cell Lymphoma

April 1, 2022 – Gilead’s Yescarta^® (axicabtagene ciloleucel) has been approved to treat adults diagnosed with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy